Parkinson's disease (PD) is a progressive neurodegenerative disorder. It has been classically described as a movement disorder involving the striato-nigral pathway characterized by resting tremor, bradykinesia, rigidity, and postural instability. It is now considered a multisystem disorder that includes motor and non-motor symptoms.
brain samples showing increases of 41.5 and 30.4% in the putamen and globus pallidus lateralis, respectively, between 60 and 90 years of age. 11 In positron-emission tomography studies of healthy living subjects, the increase in MAO-B levels in the basal ganglia is estimated to be 8% every 10 years from 23 to 86 years of age; 12 in normal aging, the average increase in MAO-B levels in all brain regions is 7.1% (±1.3%) every 10 years. 12 MAO-B inhibitors increase dopamine availability by inhibiting the breakdown of dopamine by MAO-B. 13 MAO-B inhibitors can be used in the treatment of early PD; their mechanism of action (i.e. preserving endogenous and exogenous dopamine) is unique compared with other antiparkinsonian medications. 14 The propargyl ring in its molecular structure may be important for reasons unrelated to MAO-B inhibition. Propargylamines appear to bind to glyceraldehyde-phosphate dehydrogenase (GAPDH), blocking apoptosis in certain pre-clinical models of PD, and also induce synthesis of neurotrophic factors. 15, 16 The two MAO-B inhibitors used are selegiline (selegiline hydrochloride [L-deprenyl], a levorotatory acetylenic derivative of phenethylamine 17 ) and rasagiline. Rasagiline is a secondary cyclic benzylamine and a derivative of indane, and like selegiline has a propargyl group but no amphetamine metabolites. 13, 14, [18] [19] [20] MAO-B inhibitors are well tolerated with minimal side effects when used before patients have started taking levodopa, although there is a theoretical risk for hypertensive reactions at doses significantly higher than the FDA-approved doses.
Clinical Trials of Monoamine Oxidase Type B Inhibitors in Early Parkinson's Disease

DATATOP Study
The Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) study was designed to assess the effects of treatment with selegiline and/or tocopherol on the onset of disability requiring levodopa in patients with early untreated PD. [21] [22] [23] The study involved 800
patients. The primary end-point was the onset of disability prompting the clinical decision to begin administering levodopa. There were four treatment arms: placebo, active tocopherol and deprenyl (selegiline) placebo, active selegiline and tocopherol placebo, or both active drugs.
The patients were followed for a mean of 14±6 months. Selegiline 10mg/day significantly delayed the primary end-point by about nine months, which indicates either a symptomatic or disease-modifying effect; it is impossible to differentiate these possibilities because of concerns that the one-month wash-out period was insufficient to allow complete elimination of the symptomatic effect of selegiline. Open-label extensions with selegiline 10mg/day for up to 18 months were conducted in both patients who reached and did not reach the endpoints. 24, 25 These clinical studies showed that prior treatment with selegiline did not lead to superior survival with respect to the end-point of disability requiring levodopa, and it did not reduce the occurrence of subsequent levodopa-associated adverse effects in this population. On the other hand, a long-term naturalistic study suggests that levodopatreated PD patients who had previously been treated with selegiline compared with placebo for up to seven years experienced slower motor decline and were less likely to develop freezing of gait but more likely to develop dyskinesias. 26 These findings are also consistent with either a symptomatic or disease-modifying effect as the study was not designed to differentiate between these possibilities. The 2002 American Academy of Neurology (AAN) practice parameter concluded that there was no convincing evidence to suggest a neuroprotective effect of selegiline. 27 
TEMPO Study
The Rasagiline Mesylate (TVP-1012) in Early Monotherapy for PD Outpatients (TEMPO) study was a one-year study originally designed in two parts: a six-month safety and efficacy study and a 12-month delayed start design study to assess a disease-modifying effect for rasagiline. 28, 29 Patients were randomized to treatment with either a placebo, 1mg rasagiline or 2mg rasagiline and were followed for 26 weeks. The primary end-point was the change in total Unified Parkinson Disease Rating Scale (UPDRS) score between baseline and 26 weeks of treatment (see Figure 1) .
The difference in this parameter comparing rasagiline 1 and 2mg versus placebo was -4.20 units (p<0.001) and -3.56 units (p<0.001), respectively, indicating less symptomatic worsening in both rasagiline groups compared with placebo over six months. The delayed-start study involved switching the placebo group to 2mg rasagiline at the end of 26 weeks, and all groups were followed for the next six months. At the end of one year, the change in the mean adjusted total UPDRS score was -2.3 units (p=0.01) comparing rasagiline 2mg with the delayed rasagiline 2mg group, and -1.82 units (p=0.05) comparing the rasagiline 1mg group with the delayed rasagiline 2mg group. This showed that the benefits associated with early rasagiline treatment could not be achieved with the later introduction of the same drug. 29 An extension of this study was conducted to compare long-term clinical progression of the disease as assessed by total UPDRS score in the early-start versus delayed-start groups. 30 Initially, all patients were placed on 2mg/day. However, once the initial TEMPO results showed that there was no difference in efficacy between 1 and 2mg/day, the dose given was decreased to 1mg/day. Three hundred and six subjects (85% of the 360 subjects who completed the double-blind portion of the trial) chose to participate in the open-label extension study. The average (± standard deviation [SD]) duration in the study was 3.6±2.1 years while 177 subjects received rasagiline for over five years. For the intent-to-treat analysis including all 306 subjects entering the extension study, the mean difference in change from baseline in total UPDRS score between earlyand delayed-start subjects was 2.5 units (p=0.021), corresponding to a mean relative difference of 16% (p=0.006), indicating that the early-start group had less symptomatic worsening. Similarly, for subjects who continued in the study up to database lock (n=177), the adjusted mean difference in change in total UPDRS score was 2.4 units, corresponding to a mean relative difference of 17% (p=0.002) in favor of the early-start rasagiline group. Significantly less worsening (percent change) in total UPDRS score was observed in the early-start group at 0.5, 1.5, 2.0, 3.0, 4.5, 5.0, and 5.5 years (p<0.05). 27 This suggests that the clinical benefits noted in the initial study persisted through the years even as patients were being treated with other antiparkinsonian medications.
ADAGIO Study
Recently, rasagiline has been tested in a large, prospective, multicenter trial using a delayed-start design-the Effect of Rasagiline Mesylate in Early PD patients (ADAGIO) study-to further assess its potential effects on disease progression. 31 Both the 1 and 2mg/day doses were tested using a double-blind, placebo-controlled, delayed-start study design. The primary end-point included three hierarchal analyses that had to be met in order to declare the study positive (see Figure 2) . The first end-point compared the slope of symptom progression in active drug versus placebo groups in the first nine months of the study. An assumption of the study planners was that by 12 weeks the full symptomatic effect of rasagiline would be established. A disease-modifying agent would be expected to have a shallower slope compared with placebo. The second end-point was the difference in UPDRS score at the end of 72 weeks. To demonstrate disease modification, any benefit in the form of slower progression present in the early-start group in phase 1 had to persist until the end of the study.
The third end-point evaluated the slope in the second nine months, when all patients were on active drug. A disease-modifying drug should show no difference in slope in this phase since both groups would be receiving any such disease-modifying benefit. Rasagiline 1mg/day met all three primary end-points, consistent with the possibility that the drug has a diseasemodifying effect (see Figure 3) . However, rasagiline 2mg/day failed to meet the second end-point, and some have suggested that this may be due to the very early stage of patients enrolled; in this population, the symptomatic effect of the 2mg dose might have masked any diseasemodifying effect. In an effort to explore this possibility, a post hoc analysis was performed in all subjects. Considering end-point two (change in total UPDRS score from baseline to end of study) for the 1mg dose, the difference between early and delayed start was -1.68±0.75 UPDRS units in the whole cohort, while for the quartile with the highest baseline UPDRS score it was -3.40±1.66. For 2mg, the change was 0.36±0.68 in the whole cohort and -3.63±1.72 in the highest quartile. 32 Both doses met all three hierarchical end-points when tested in subjects whose baseline UPDRS scores fell into the highest quartile. That these results for the highest quartile analysis were statistically significant is remarkable since the number of patients included in this analysis was much smaller than that in Early-start (rasagiline-rasagiline) the prospectively identified cohorts, which accordingly reduced the statistical power of the analysis to find a difference (see Figure 3) .
Discussion
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